

# Protein supplementation in critical illness: why, when and how?

Citation for published version (APA):

Bels, J. L. M., Abdelhamid, Y. A., & van de Poll, M. C. G. (2023). Protein supplementation in critical illness: why, when and how? *Current Opinion in Clinical Nutrition and Metabolic Care*, 26(2), 146-153. <https://doi.org/10.1097/MCO.0000000000000912>

## Document status and date:

Published: 01/03/2023

## DOI:

[10.1097/MCO.0000000000000912](https://doi.org/10.1097/MCO.0000000000000912)

## Document Version:

Publisher's PDF, also known as Version of record

## Document license:

Taverne

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.



# Protein supplementation in critical illness: why, when and how?

Julia L.M. Bels<sup>a,b</sup>, Yasmine Ali Abdelhamid<sup>c,d</sup>  
and Marcel C.G. van de Poll<sup>a,b,e</sup>

## Purpose of review

In critically ill patients, optimal protein provision remains a challenge given the wide range in recommended protein delivery in international guidelines and the lack of robust, high quality evidence. As patients are confronted with poor functional outcomes after admission, often attributed to muscle wasting and persisting for multiple years, there is a pressing need for optimal nutritional strategies in the ICU, particularly including protein. This review will discuss the recent literature with regard to purpose, timing and mode of protein delivery.

## Recent findings

Recent studies on the effect of dose and timing of protein on clinical and functional outcomes are largely observational in nature and the protein delivery considered as “high” still often only nears the lower end of current recommendations. The majority of trials observed no effect of protein supplementation on mortality, muscle strength or function, though some report attenuation of muscle volume loss, especially when combined with muscle activation. There is no strong evidence that ICU patients should receive supplementation with any specific amino acids.

## Summary

Though adequate protein provision is likely important, it is difficult to come to a uniform conclusion regarding dosing and timing due to conflicting results in mostly observational studies as well as different cut-off values for high, moderate and low protein intake. This topic is currently subject to large clinical trials.

## Keywords

amino acids, critical illness, functional outcomes, nutritional strategies, protein supplementation

## INTRODUCTION

The optimal protein provision to critically ill patients remains unclear and protein requirements most likely differ for patients with varying diagnoses and in different phases of their disease course. Recent international critical care nutrition guidelines recommend that critically ill patients receive protein at a dose of 1.2–2.0 g/kg of body weight/day [1<sup>a</sup>,2]. However, the evidence for this recommendation is weak with a paucity of high quality randomized controlled trials (RCTs) to support it. There is an urgent need for strong evidence regarding the optimal dose and type of protein supplementation and possible changes in protein requirements during the course of critical illness.

The aim of this review is to describe the importance of protein supplementation in critical illness, the recent developments in the understanding of protein absorption and metabolism and to provide

insight into timing and mode of protein delivery (as a macronutrient or amino acids), with the purpose of providing practical guidance for clinicians at the bedside, essentially answering the questions: “why, when and how?” (Fig. 1).

<sup>a</sup>Department of Intensive Care Medicine, Maastricht University Medical Centre, <sup>b</sup>NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands, <sup>c</sup>Intensive Care Specialist, Intensive Care Unit, Royal Melbourne Hospital, <sup>d</sup>Department of Critical Care, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia and <sup>e</sup>Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands

Correspondence to Julia L.M. Bels, M.D., Maastricht University Medical Centre, Maastricht 6229HX, The Netherlands.

E-mail: julia.bels@mumc.nl

**Curr Opin Clin Nutr Metab Care** 2023, 26:146–153

DOI:10.1097/MCO.0000000000000912

## KEY POINTS

- Critically ill patients demonstrate anabolic resistance to dietary protein in absence of malabsorption, highlighting an important therapeutic target in the prevention of muscle wasting.
- Benefits of early high protein provision remain controversial due to a lack of robust data.
- There is limited evidence to support the use of specific amino acids to improve outcomes in the ICU.
- Several large randomized clinical trials are being performed to establish the effect of high protein delivery on clinical and functional patient centred outcomes.
- Protein supplementation in combination with muscle activation, such as electrical muscle stimulation or physical therapy, should be further explored.


## WHY SHOULD WE SUPPLEMENT PROTEIN?

Survivors of the intensive care unit (ICU) often experience poor functional outcomes that can persist for many years after discharge and result in impaired quality of life, increased healthcare use and delayed return to work [4,5,31]. Optimal maintenance of nutritional status during ICU admission is seen as one of the key elements to improve these functional outcomes, as functional deficits are often attributed to severe muscle wasting [5]. Despite their importance, actual nutritional targets are frequently not met due to feed interruptions, gastrointestinal intolerance or feeding protocol deviations with the typical amount of protein actually delivered approximating 0.6–1.2 g/kg/day [6<sup>■</sup>,7,8]. In light of this, the provision of 1.2 g/kg/day of protein is in most

retrospective observational studies regarded as “high protein” nutrition.

The evidence for the benefit of increased protein supplementation is hitherto still limited to observational data and some small RCTs that have not been adequately powered to detect relevant differences in clinical outcomes. Zusman *et al.* [9] demonstrated a linear association between protein intake and long-term survival, suggesting that the optimum protein dose for critically ill patients is even higher than the pragmatically determined amount of 1.2 or 1.3 g/kg/day [1<sup>■</sup>,2]. Multiple retrospective studies, both in the past and more recently, have shown a beneficial effect of protein on mortality [8,10], muscle mass and strength [11] or patient-centred outcomes [12], yet another cohort ( $n=32$ ) did not show an association between protein delivery and degree of muscle loss [13].

A large meta-analysis of 19 RCTs ( $n=1731$  participants) by Lee *et al.* [14<sup>■</sup>] found no difference in mortality or other clinical or patient-centred outcomes between higher and lower protein doses (pooled mean protein  $1.3 \pm 0.48$  vs.  $0.9 \pm 0.30$  g/kg/day, respectively) with similar energy delivery. The majority of included studies were at moderate risk of bias, with small sample sizes and single centre design. Of note, the protein delivery in the ‘high protein’ group still only nears the lower end of current recommendations. They did find, in five small studies ( $n=273$ ), significantly attenuated muscle loss (mean difference  $-3.44\%$  per week, 95% confidence interval [CI]  $-4.99$  to  $-1.90$ ) when patients were provided with higher protein intake. A recent review [15] has summarized all RCTs investigating dietary protein interventions on muscle mass, strength or function. The four most recent of these six RCTs failed to demonstrate any beneficial effect of protein supplementation



**FIGURE 1.** A summary of the recent evidence for the rationale, optimal timing and methods of protein supplementation in critical illness. ICU, intensive care unit; HMB,  $\beta$ -hydroxy- $\beta$ -methylbutyrate.

[16<sup>22</sup>,17,18<sup>23</sup>,19<sup>24</sup>]. Other recent meta-analyses also have not reported improved outcomes with higher protein delivery [20<sup>25</sup>,21], but these included studies with significant differences in calories between groups or studies that tested immunonutrition, both of which may have confounding effects on patient outcomes.

More recently, the first RCT using computed tomography to evaluate diaphragm atrophy in 41 patients with high (1.7 g/kg/day) vs. standard (1.1 g/kg/day) protein provision, found a significant difference in recovery of diaphragm muscle mass at weeks 4 and 5 of ICU, after a similar degree of atrophy occurred during the first three weeks [22<sup>26</sup>]. These findings would suggest additional protein supplementation does not protect from diaphragm atrophy, yet aids in its recovery. However, this did not translate in improvement of other endpoints such as weaning from mechanical ventilation, ICU length of stay or mortality. Of note, this was an open-label study and calorie delivery differed significantly between the standard and high protein intake groups (26 vs. 33 kcal/kg/day,  $P < 0.001$ ), indicating possible bias and confounding. Lastly, only 7 vs. 7 and 3 vs. 4 patients contributed data on diaphragm muscle mass in weeks 4 and 5, and this loss to follow up potentially compromises the validity of the study findings.

Currently, several large RCTs addressing the effectiveness of high dose protein supplementation on clinical and functional patient-centred outcomes are being performed and will provide robust data to inform future clinical practice guidelines: PRE-CISE-trial (2.0 vs. 1.2 g/kg/day of protein via isocaloric enteral nutrition (EN); NCT04633421; recruiting), TARGET-PROTEIN [23<sup>27</sup>] (isocaloric enteral feeds with protein content 100 g/l vs. 63 g/l; ACTRN12618001829202; recruiting), EFFORT and EFFORT-outcomes [24] ( $\geq 2.2$  vs.  $\leq 1.2$  g/kg/day of protein via EN, parenteral nutrition (PN) or both; NCT03160547 and NCT04931940).

## PROTEIN ABSORPTION AND METABOLISM

Research on nutrition in critical illness has generally focused on the actual amount of nutrients administered to patients. However, studies utilizing glucose and lipid tracers suggest that maldigestion and malabsorption are frequently encountered in critical illness, which may severely jeopardize nutritional adequacy despite the administration of a targeted amount of nutrition [25].

Van Gassel *et al.* [26<sup>28</sup>] studied protein absorption in critically ill patients and healthy volunteers that received an enteral bolus of 4 g of protein and a 3-O-

methyl-D-glucose (3-OMG) tracer. They found a blunted rise in plasma levels of essential amino acids in ICU patients after the administration of the study feed. However, after one hour, essential amino acid levels were identical in both groups. Interestingly, 3-OMG plasma levels rose less sharply and remained lower in critically ill patients than in healthy volunteers for at least 150 min, suggesting glucose malabsorption is not invariably accompanied by protein malabsorption. Chapple *et al.* [27<sup>29</sup>] compared protein digestion, absorption and postprandial muscle synthesis in 15 critically ill patients vs. 10 healthy controls, by providing stable isotope tracers of the essential amino acids phenylalanine and leucine intravenously, followed by a bolus of labelled intact protein intraduodenally. In line with the findings of van Gassel *et al.*, a higher and more rapid peak of exogenous phenylalanine appearance was found in healthy controls that equalised between both groups during the 6 h postprandial period. These findings suggest that protein absorption is not severely impaired in the critically ill. They did, however, find that the incorporation of dietary protein into myofibrillar protein in muscle biopsies was 60% less in critically ill patients, demonstrating anabolic resistance to dietary protein. Of note, muscle breakdown rates were not studied here and might provide an alternative therapeutic target, as pointed out by Puthucherry *et al.* [28] in their commentary.

Whether anabolic resistance can be overcome by increasing protein provision remains to be evaluated. It may be that impaired synthesis or increased breakdown are not affected by protein supply, in which case muscle catabolism should rather be treated with interventions directed at overcoming anabolic resistance than with enhanced protein nutrition.

## TIMING OF PROTEIN SUPPLEMENTATION

When to start or increase protein supplementation is controversial, since several studies have cast doubt on the safety of high protein provision in critical illness. A posthoc analysis of the EPaNIC trial showed that the adverse outcome of early PN in critically ill patients was particularly associated with the amount of protein administered, which the authors ascribed to the inhibitory effect of early protein supplementation on autophagy [29]. Some retrospective studies support the observation that early high protein may be harmful [7,30], whereas other data point to a beneficial effect of early (<4 days) [31], late (4–7 days) [32] or overall higher protein provision with regard to survival (Table 1).

Of note, an international prospective cohort study in 1172 ICU patients modelled the association between calorie and protein intake during the early

**Table 1.** Overview of observational studies investigating the effect of varying timing and dose of protein supplementation.

Timing	Author, year	Study design	No. of studied (sub)group	Protein delivery <sup>a</sup> intervention vs. control	Effect of higher dose protein intervention
Early (days 1–3)	Koekkoek, 2019 [1 <sup>■</sup> ]	Retrospective cohort	455	>0.8 vs. <0.8	Decreased 6-month mortality (HR 1.23, 95% CI 1.04–1.46)
	Bendavid, 2019 [2]	Retrospective cohort	2253	0.93 vs. 0.39	Decreased 2-month mortality (adjusted <sup>b</sup> HR 0.83, 95% CI 0.71–0.97)
	De Koning, 2020 [3 <sup>■</sup> ]	Retrospective cohort	89	>1.2 vs. <0.8	Increased 6-month mortality (HR 3.90, 95% CI 1.51–10.12) in nonseptic patients
Late (days 4–7)	Koekkoek, 2019 [1 <sup>■</sup> ]	Retrospective cohort	291; 415	>1.2 vs. <0.8; >1.2 vs. 0.8–1.2	Decreased 6-month mortality (HR 0.62, 95% CI 0.46–0.85); increased 6-month mortality (HR 1.40, 95% CI 1.09–1.79)
	De Koning, 2020 [3 <sup>■</sup> ]	Retrospective cohort	273; 81	>1.2 vs. 0.8–1.2; >1.2 vs. <0.8	Increased 6-month mortality (HR 1.55; 95% CI 1.00 <sup>c</sup> –2.39) in septic patients; decreased 6-month mortality (HR 0.38, 95% CI 0.16–0.89) in nonseptic patients
	Van Ruijven, 2022 [4]	Retrospective cohort	2618	≥1.2 vs. <1.2 at day 4	Decreased ICU mortality (adjusted <sup>d</sup> HR 0.49, 95% CI 0.39–0.62) and decreased hospital mortality (adjusted <sup>d</sup> HR 0.48, 95% CI 0.39–0.60)
Overall (varying doses in days 1–15)	Hartl, 2022 [5]	Retrospective cohort using piece-wise exponential additive mixed modelling	16489	<0.8 on day 1–4 & 0.8–1.2 on day 5–11 vs. <0.8 on day 1–11;	Decreased hospital mortality (minimum HR 0.75, 95% CI 0.64–0.87) and increased live hospital discharge (maximum HR 1.98 (95% CI 1.72–2.28));
				>1.2 on days 1–11 vs. 0.8–1.2 on day 1–11	decreased live hospital discharge <sup>e</sup> (minimum HR 0.31, 95% CI 0.24–0.39);
	Matejovic, 2022 [6 <sup>■</sup> ]	Prospective cohort using piece-wise exponential additive mixed modelling	1172	0.8–1.2 on days 1–4 & >1.2 on days 5–11 vs. 0.8–1.2 on day 1–11	decreased live hospital discharge <sup>e</sup> (minimum HR 0.19, 95% CI 0.15–0.24)
				0.8–1.2 vs. <0.8 or >1.2;	Higher probability of successful weaning from IMV (maximum HR 2.60, 95% CI 1.09–6.23);
				>1.2 irrespective of timing vs. 0.8–1.2 on days 1–15	lower probability of successful weaning from IMV (minimum HR 0.28, 95% CI 0.12–0.65)

95% CI, 95% confidence interval; HR, hazard ratio; ICU, intensive care unit; IMV, invasive mechanical ventilation.

<sup>a</sup>Protein delivery is expressed as grams of protein per kg body weight per day (g/kg/day).

<sup>b</sup>Adjusted for age, sex, weight, parenteral nutrition, mean delivered calories, mean daily protein received after the first 3 days, administration of vasopressors, SOFA score, year of study, and total hospital stay.

<sup>c</sup>Lower limit of 95% confidence interval is 1.004.

<sup>d</sup>Adjusted for APACHE II score, relative energy provision, BMI, and age.

<sup>e</sup>Results were qualitatively changed by a sensitivity analysis due to the assumption of a standard protein intake after ICU discharge. Without those assumptions, a high protein intake appeared to neither worsen nor improve ICU outcomes.

or later stage of ICU admission and outcomes (weaning from mechanical ventilation and survival) and found harm with protein provision exceeding 1.2 g/kg during at least 15 days [6<sup>■</sup>]. A significant association was observed between moderate protein intake (0.8–1.2 g/kg) from day 1 to day 15 and earlier weaning from invasive mechanical ventilation, yet not with survival, whereas high protein (>1.2 g/kg) was associated with prolonged mechanical ventilation. Using comparable analysis methods on data from a point prevalence study of nutritional practice in ICU ( $n = 16\,489$ ), Hartl *et al.* [33<sup>■</sup>] showed that moderate (0.8–1.2 g/kg/day) late (day 5–11) protein administration was associated with a lower rate of in-hospital death and higher rate of live hospital discharge, whereas high protein administration (>1.2 g/kg/day) was associated with increased mortality, irrespective of disease stage.

Taken together, there are substantially conflicting results regarding the association between timing of protein supplementation and outcome in critical illness. The comparability of these studies is hampered by the different cut-off values that are used to distinguish high, moderate and low protein intake. Moreover, although most observational studies attempt to correct for potential confounders, the possible causality of the observed associations between protein intake and clinical outcomes cannot be established. These discordant findings make it difficult to formulate firm recommendations regarding timing of protein supplementation and large prospective RCTs are required.

Apart from the timing and dose of protein, there is increasing interest in other factors influencing muscle mass and strength in critical illness, such as electrostimulation and early physical exercise [34,35]. Nakamura *et al.* [36<sup>■</sup>] randomized 117 critically ill patients to receive high (1.5 g/kg/day) or medium (0.8 g/kg/day) protein intake. Sixty patients, evenly distributed amongst both groups also received daily electrical muscle stimulation (EMS). Femoral muscle loss was greater in the medium protein group, although this difference only reached statistical significance in groups who received EMS. However, the high protein formula contained whey protein, as opposed to soy in the medium protein group, possibly influencing the results due to differing leucine contents (an important anabolic stimulus) and its subsequent different effects on myofibrillar synthesis. In addition, the intervention did not result in differences in patient centred outcomes such as activities of daily living or quality of life at hospital discharge.

In a similar intervention in a neurocritical care setting, high protein intake (1.5 g/kg/day) combined with EMS of the quadriceps muscle compared to

usual care (0.9 g/kg/day) resulted in less muscle atrophy (6.5% vs. 12.5%,  $P = 0.01$ ), yet no difference in lower extremity mobility was found [37]. It should be noted however that muscle function may be difficult to measure in neurologically impaired patients. Increasing the amount of activated muscle may improve functional outcomes. To investigate this, Kagan *et al.* [38] performed a randomized pilot trial in 41 patients comparing three groups: conventional physiotherapy, cycle ergometry with standard EN, and cycle ergometry with protein-enriched EN. They found no differences with regard to duration of mechanical ventilation, length of ICU or hospital stay, ICU mortality, or re-intubation rate, which might be attributed to the small sample size. Moreover, they did not study long-term functional outcomes, as opposed to de Azevedo *et al.* [39<sup>■</sup>] who studied 87 patients receiving high protein and early exercise and 94 patients receiving routine nutrition and physiotherapy in a randomized controlled trial. They found a significant difference in their primary endpoint, the physical component summary (PCS) of the Short Form Survey (SF-36), at three and six months favouring the intervention group. Remarkably, they found a difference in mortality (33 vs. 54%,  $P = 0.005$ ) at six months, which has not previously been established in studies of protein administration and exercise in ICU and is likely to represent a Type I error relating to the very high mortality rates in both groups (31% and 52%).

Overall, the available literature suggests that muscle activation combined with protein administration may be more effective at attenuating muscle loss and positively influencing long-term functional outcomes. Larger prospective studies to confirm these preliminary observations are needed.

## WHOLE PROTEIN OR INDIVIDUAL AMINO ACIDS?

Though international critical care nutrition guidelines recommend protein supplementation, they do not specify what type of protein should be provided or whether there is a role for supplementation of individual amino acids in critical illness. Whether supplementation with individual amino acids, rather than whole protein, can overcome the anabolic resistance of muscle and improve outcomes in critical illness remains uncertain. The safety of such an approach is also unclear, given that administration of large nonphysiological doses of amino acids may theoretically suppress autophagy, increase ureagenesis and supply precursors of toxic neuromediators. One of the largest RCTs (the Nephro-Protective trial,  $n = 474$ ) [40] of amino acid

supplementation in critically ill patients (up to 100 g/day of intravenous amino acids vs. standard care) showed that amino acid supplementation did not preserve renal function and resulted in significantly higher serum urea levels. Previous evidence also suggests increased mortality with the use of intravenous glutamine in ICU patients with multi-organ failure [41] and caution is warranted.

The branched chain amino acid leucine is one of the most potent stimulators of muscle protein synthesis and acts via stimulation of the mammalian target of rapamycin (mTOR) pathway [42<sup>■</sup>]. Its metabolite,  $\beta$ -hydroxy- $\beta$ -methylbutyrate (HMB), also stimulates muscle synthesis via the mTOR pathway but, in addition, attenuates proteasome pathways that lead to muscle protein catabolism. HMB has been found to increase muscle mass and strength in a variety of clinical conditions including cancer cachexia, end-stage renal failure, HIV infection and older age [43]. There has been only one recent study of leucine supplementation [44<sup>■</sup>] and three recent studies of HMB supplementation in critical illness [18<sup>■</sup>, 19<sup>■</sup>, 45]. Wandrag *et al.* [44<sup>■</sup>] conducted a feasibility study of leucine-enriched amino acid supplementation in critically ill trauma patients but reported difficulties with recruitment, administration of the supplement five times per day, and assessment of physiological outcome measures including muscle thickness by ultrasound and nitrogen balance.

A single centre open-label RCT in Japan of 88 participants evaluated the effect of HMB (total 3 g/day) in combination with arginine and glutamine from day 2 of ICU admission on femoral muscle volume loss measured by CT [18<sup>■</sup>]. All patients received early rehabilitation and electrical muscle stimulation daily. There was no difference in the primary outcome at day 10 of ICU admission, but any effect of HMB is difficult to elucidate in this trial because HMB was administered in conjunction with arginine and glutamine. Supinski *et al.* [45] randomised 83 mechanically ventilated patients in a blinded fashion to one of four groups for 10 days: HMB (3 g/day), HMB (3 g/day) and the omega-3 fatty acid eicosapentaenoic acid, eicosapentaenoic acid alone, or control. There was no difference between groups in diaphragm strength, quadriceps strength or ultrasound-derived diaphragm thickness.

A smaller partially blinded single-centre RCT [19<sup>■</sup>] randomised 30 mechanically ventilated patients to HMB (3 g/day) or placebo for a longer period of time (up to 30 days). There was no difference in the primary outcome of ultrasound-derived rectus femoris muscle loss between days 4 and 15. However, net protein breakdown as measured by amino acid tracer methodology was reduced in the

HMB intervention group. Further large studies of HMB supplementation in critical illness are needed and these should evaluate HMB in the absence of other supplements, continue supplementation into the recovery phase after ICU discharge when anabolic resistance may be reduced [46] and evaluate physiological outcomes to further improve our mechanistic understanding.

There have been limited recent studies of supplementation with other amino acids in critical illness. A large multicentre double-blind RCT has evaluated glutamine supplementation in burned patients [47<sup>■</sup>], given that several small single-centre RCTs have suggested reduced mortality and length of hospital stay with glutamine supplementation and international nutrition guidelines for major burns recommend glutamine supplementation. A total of 1029 patients were randomised to enteral glutamine (0.5 g/kg/day) or placebo. Glutamine supplementation did not reduce the time to discharge alive from hospital. Although this study was affected by slow recruitment, leading to alteration of the sample size and primary outcome, the findings suggest that routine glutamine supplementation in burned patients should be reconsidered.

There has also been recent interest in the conditionally essential amino acid glycine, which appears to have anti-inflammatory effects and restores the anabolic sensitivity of skeletal muscle to leucine in animal models of muscle wasting including sepsis [48]. A recent randomised double-blind crossover trial of 36 malnourished chronic haemodialysis patients demonstrated that glycine supplementation (7 g/day) improved fat-free mass index as measured by bioelectrical impedance analysis when compared with branched chain amino acid supplementation [49] and studies in ICU patients are ongoing (ACTRN12618000409279).

## CONCLUSION

Adequate protein provision may be important to prevent muscle loss in critically ill patients and improve functional outcomes. However, the optimal dose of protein remains uncertain and is currently subject to large clinical trials. There is no strong evidence that ICU patients should receive supplementation with any specific amino acids. Future studies of whole protein or amino acid supplementation should initially test one supplement at a time, instead of multiple agents in conjunction. Furthermore, there is an urgent need for mechanistic studies of protein metabolism, muscle protein kinetics and muscle pathophysiology in critical illness to inform the selection of protein type, dose and timing in future large clinical trials. Such

mechanistic studies will also provide vital information about the best methods to monitor muscle loss at the bedside. Lastly, future clinical trials should focus on protein supplementation in conjunction with exercise in the ICU or in the recovery phase of critical illness after ICU discharge, when muscle anabolic resistance decreases and patient mobility increases.

## Acknowledgements

None.

## Financial support and sponsorship

None.

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Compher C, Bingham AL, McCall M, *et al.* Guidelines for the provision of nutrition support therapy in the adult critically ill patient: the American Society for Parenteral and Enteral Nutrition. *JPEN J Parenter Enteral Nutr* 2022; 46:12–41.

This is an update of the ASPEN clinical nutrition guidelines for critically ill patients and includes critical appraisal of recent evidence regarding protein provision and outcomes in critical illness.

2. Sinswager P, Blaser AR, Berger MM, *et al.* ESPEN guideline on clinical nutrition in the intensive care unit. *Clin Nutr* 2019; 38:48–79.
3. Bels JLM, van Gassel RJJ, Timmerman L, *et al.* One-year outcomes of mechanically ventilated COVID-19 ICU survivors: a prospective cohort study. *Am J Respir Crit Care Med* 2022; 206:777–780.

A prospective study in mechanically ventilated COVID-19 ICU survivors detailing multidomain assessment of radiological, respiratory, functional, and patient-reported outcomes at three and twelve months following hospital discharge. The persisting sequelae objectified at three months significantly improved, though complaints of fatigue and dyspnea remained largely unchanged.

4. van Gassel RJJ, Bels J, Remij L, *et al.* Functional outcomes and their association with physical performance in mechanically ventilated coronavirus disease 2019 survivors at 3 months following hospital discharge: a cohort study. *Crit Care Med* 2021; 49:1726–1738.
5. Batt J, Herridge MS, Dos Santos CC. From skeletal muscle weakness to functional outcomes following critical illness: a translational biology perspective. *Thorax* 2019; 74:1091–1098.
6. Matejovic M, Huet O, Dams K, *et al.* Medical nutrition therapy and clinical outcomes in critically ill adults: a European multinational, prospective observational cohort study (EuroPN). *Crit Care* 2022; 26:143.

An international prospective cohort study in 1172 ICU patients admitted for five days or more, in which different trajectories (i.e. varying dose and timing) of protein administration were modelled. Only a significant association between moderate protein intake (0.8–1.2 g/kg/day) from day 1 to day 15 and earlier weaning from invasive mechanical ventilation was found, yet no associations with survival.

7. de Koning MLY, Koekkoek W, Kars J, van Zanten ARH. Association of PROtein and CAloric Intake and Clinical Outcomes in Adult SEPTic and Non-Septic ICU Patients on Prolonged Mechanical Ventilation: the PROCA-SEPT Retrospective Study. *JPEN J Parenter Enteral Nutr* 2020; 44:434–443.
8. Silvah JH, de Lima CMM, Nicoletti CF, *et al.* Protein provision and lower mortality in critically ill patients with COVID-19. *Clin Nutr ESPEN* 2021; 45:507–510.
9. Zusman O, Theilla M, Cohen J, *et al.* Resting energy expenditure, calorie and protein consumption in critically ill patients: a retrospective cohort study. *Crit Care* 2016; 20:367.
10. Suzuki G, Ichibayashi R, Yamamoto S, *et al.* Effect of high-protein nutrition in critically ill patients: a retrospective cohort study. *Clin Nutr ESPEN* 2020; 38:111–117.

11. Matsushima S, Yoshida M, Yokoyama H, *et al.* Effects on physical performance of high protein intake for critically ill adult patients admitted to the intensive care unit: a retrospective propensity-matched analysis. *Nutrition* 2021; 91–92:111407.

12. Lu SY, Otero TMN, Yeh DD, *et al.* The association of macronutrient deficit with functional status at discharge from the intensive care unit: a retrospective study from a single-center critical illness registry. *Eur J Clin Nutr* 2022; 76:551–556.

13. Lambell KJ, Goh GS, Tierney AC, *et al.* Marked losses of computed tomography-derived skeletal muscle area and density over the first month of a critical illness are not associated with energy and protein delivery. *Nutrition* 2021; 82:111061.

14. Lee ZY, Yap CSL, Hasan MS, *et al.* The effect of higher versus lower protein delivery in critically ill patients: a systematic review and meta-analysis of randomized controlled trials. *Crit Care* 2021; 25:260.

This systematic review and meta-analysis of 19 RCTs found no improvement in clinical or patient centred outcomes with higher protein delivery when compared to lower protein delivery in critical illness.

15. Chapple LS, van Gassel RJJ, Rooyackers O. Protein metabolism in critical illness. *Curr Opin Crit Care* 2022; 28:367–373.

16. Dresen E, Weißbrich C, Fimmers R, *et al.* Medical high-protein nutrition therapy and loss of muscle mass in adult ICU patients: a randomized controlled trial. *Clin Nutr* 2021; 40:1562–1570.

A RCT in 42 critically ill patients comparing muscle loss as measured via ultrasonography in groups that received 1.2 vs. 1.8 g protein/kg/day. No significant differences in loss of muscle mass were found, nor differences in endpoints such as length of stay, duration of mechanical ventilation or mortality.

17. McNelly AS, Bear DE, Connolly BA, *et al.* Effect of intermittent or continuous feed on muscle wasting in critical illness: a phase 2 clinical trial. *Chest* 2020; 158:183–194.

18. Nakamura K, Kihata A, Naraba H, *et al.*  $\beta$ -Hydroxy- $\beta$ -methylbutyrate, arginine, and glutamine complex on muscle volume loss in critically ill patients: a randomized control trial. *JPEN J Parenter Enteral Nutr* 2020; 44:205–212.

This is the largest RCT of HMB supplementation in critical illness. HMB, when administered in conjunction with arginine and glutamine, did not attenuate femoral muscle volume loss.

19. Viana MV, Becce F, Pantet O, *et al.* Impact of  $\beta$ -hydroxy- $\beta$ -methylbutyrate (HMB) on muscle loss and protein metabolism in critically ill patients: a RCT. *Clin Nutr* 2021; 40:4878–4887.

This small single centre RCT of HMB supplementation was unique because the intervention was continued for a longer period of time (up to 30 days) and secondary outcomes included amino acid metabolism measured with tracer methodology.

20. Fetterplace K, Gill BMT, Chapple LS, *et al.* Systematic review with meta-analysis of patient-centered outcomes, comparing international guideline-recommended enteral protein delivery with usual care. *JPEN J Parenter Enteral Nutr* 2020; 44:610–620.

This systematic review of 6 RCTs in critically ill patients that reported enteral protein doses <1.2 g/kg/day compared to international recommended doses ( $\geq 1.2$  g/kg/day) found no effect on mortality and insufficient data on outcomes of muscle mass, strength or function available to conduct meta-analysis.

21. Davies ML, Chapple LS, Chapman MJ, *et al.* Protein delivery and clinical outcomes in the critically ill: a systematic review and meta-analysis. *Crit Care Resusc* 2017; 19:117–127.

22. Zhang Q, Zhou J, Zhu D, Zhou S. Evaluation of the effect of high protein supply on diaphragm atrophy in critically ill patients receiving prolonged mechanical ventilation. *Nutr Clin Pract* 2022; 37:402–412.

First single-center RCT ( $n=41$ ) evaluating diaphragm atrophy using computed tomography. They found a significant difference in recovery of diaphragm muscle mass in patients with high protein delivery (1.7 g/kg/day) in weeks 4 and 5 of ICU admission compared to standard protein (1.1 g/kg/day), after a similar initial degree of atrophy, which did not translate in improved weaning from mechanical ventilation, shorter ICU length of stay or improved mortality.

23. Chapple LS, Summers MJ, Bellomo R, *et al.* Use of a high-protein enteral nutrition formula to increase protein delivery to critically ill patients: a randomized, blinded, parallel-group, feasibility trial. *JPEN J Parenter Enteral Nutr* 2021; 45:699–709.

This is the feasibility trial preceding the TARGET PROTEIN multicentre RCT examining higher versus lower protein dosing in ICU. This is one of the first RCTs of augmented protein delivery to ICU patients while maintaining isocaloric isovolumetric delivery.

24. Heyland DK, Patel J, Bear D, *et al.* The effect of higher protein dosing in critically ill patients: a multicenter registry-based randomized trial: the EF-FORT trial. *JPEN J Parenter Enteral Nutr* 2019; 43:326–334.

25. Reintam Blaser A, Deane AM, Preiser J, *et al.* Enteral feeding intolerance: updates in definitions and pathophysiology. *Nutr Clin Pract* 2021; 36:40–49.

26. van Gassel RJJ, van de Poll MCG, Schaap FG, *et al.* Postprandial rise of essential amino acids is impaired during critical illness and unrelated to small-intestinal function. *JPEN J Parenter Enteral Nutr* 2022; 46:114–122.

This physiological study studied amino acid concentrations after a postpyloric delivered bolus of protein and a 3-O-methyl-d-glucose (3OMG) tracer in healthy volunteers and critically ill patients. Early postprandial rise of EAA is blunted in ICU patients and unrelated to glucose absorption.

27. Chapelle LS, Kouw IWK, Summers MJ, *et al.* Muscle protein synthesis following protein administration in critical illness. *Am J Respir Crit Care Med* 2022; 206:740–749.
- A physiological study that found muscle protein synthesis is reduced in ICU patients compared to healthy volunteers, despite normal digestion and absorption of labelled protein delivered intraduodenally.
28. Puthucherry Z, Rooyackers O. Anabolic resistance: an uncomfortable truth for clinical trials in preventing intensive care acquired weakness and physical functional impairment. *Am J Respir Crit Care Med* 2022; 206:660–661.
29. Casaer MP, Wilmer A, Hermans G, *et al.* Role of disease and macronutrient dose in the randomized controlled EPaNIC trial: a post hoc analysis. *Am J Respir Crit Care Med* 2013; 187:247–255.
30. Koekkoek W, van Setten CHC, Olthof LE, *et al.* Timing of PROTEin INtake and clinical outcomes of adult critically ill patients on prolonged mechanical VENTilation: The PROTINVENT retrospective study. *Clinical nutrition* 2018; 38:883–890.
31. Bendavid I, Zusman O, Kagan I, *et al.* Early administration of protein in critically ill patients: a retrospective cohort study. *Nutrients* 2019; 11:106.
32. van Ruijven IM, Stapel SN, Girbes ARJ, Weijs PJM. Early high protein provision and mortality in ICU patients including those receiving continuous renal replacement therapy. *Eur J Clin Nutr* 2022; 76:1303–1308.
33. Hartl WH, Kopper P, Bender A, *et al.* Protein intake and outcome of critically ill patients: analysis of a large international database using piece-wise exponential additive mixed models. *Crit Care* 2022; 26:7.
- Large ( $n = 16,489$ ) study that modelled associations between dosage and timing of protein administration on outcomes in critically ill patients. Moderate (0.8–1.2 g/kg/day) late (day 5–11) protein administration was associated with a lower rate of in-hospital death and higher rate of live hospital discharge. Earlier (day 1–4) protein administration was not associated with improved outcomes.
34. Graham ZA, Lavin KM, O'Bryan SM, *et al.* Mechanisms of exercise as a preventive measure to muscle wasting. *Am J Physiol Cell Physiol* 2021; 321: C40–C57.
35. Stokes T, Mei Y, Seo F, *et al.* Dairy and dairy alternative supplementation increase integrated myofibrillar protein synthesis rates, and are further increased when combined with walking in healthy older women. *J Nutr* 2022; 152:68–77.
36. Nakamura K, Nakano H, Naraba H, *et al.* High protein versus medium protein delivery under equal total energy delivery in critical care: a randomized controlled trial. *Clin Nutr* 2021; 40:796–803.
- RCT evaluating the effect of high (1.5 g/kg/day) versus medium (0.8 g/kg/day) protein delivery on muscle volume loss, with implementation of electrical muscle stimulation (EMS) in the second period of the study. Only in the subgroup that received EMS, an attenuation of muscle loss was detected in the group receiving increased protein delivery compared to the medium protein intake.
37. Badjatia N, Sanchez S, Judd G, *et al.* Neuromuscular electrical stimulation and high-protein supplementation after subarachnoid hemorrhage: a single-center phase 2 randomized clinical trial. *Neurocrit Care* 2021; 35:46–55.
38. Kagan I, Cohen J, Bendavid I, *et al.* Effect of combined protein-enriched enteral nutrition and early cycle ergometry in mechanically ventilated critically ill patients—a pilot study. *Nutrients* 2022; 14:1589.
39. de Azevedo JRA, Lima HCM, Frota P, *et al.* High-protein intake and early exercise in adult intensive care patients: a prospective, randomized controlled trial to evaluate the impact on functional outcomes. *BMC Anesthesiol* 2021; 21:283.
- RCT ( $n = 181$ ) that compared high protein and early exercise to routine care and found found large difference in mortality (33 vs. 54%,  $P = 0.005$ ) at six months, as well as a significant difference in the physical component summary (PCS) of the Short Form Survey (SF-36), at 3 and 6 months favouring the intervention group.
40. Doig GS, Simpson F, Bellomo R, *et al.* Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial. *Intensive Care Med* 2015; 41:1197–1208.
41. Heyland D, Muscedere J, Wischmeyer PE, *et al.* A randomized trial of glutamine and antioxidants in critically ill patients. *N Engl J Med* 2013; 368:1489–1497.
42. Bear DE, Rooyackers O. HMB and leucine supplementation during critical illness and recovery. *Curr Opin Clin Nutr Metab Care* 2022; 25:88–92.
- This narrative review outlines the mechanisms of action of leucine and HMB and reviews the recent studies of leucine and HMB in critical illness.
43. Bear DE, Langan A, Dimidi E, *et al.*  $\beta$ -Hydroxy- $\beta$ -methylbutyrate and its impact on skeletal muscle mass and physical function in clinical practice: a systematic review and meta-analysis. *Am J Clin Nutr* 2019; 109:1119–1132.
44. Wandrag L, Brett SJ, Frost GS, *et al.* Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study. *Trials* 2019; 20:561.
- This is the only study of leucine supplementation in critical illness and demonstrates the challenges of delivering such nutritional interventions and assessing physiological outcome measures in the ICU.
45. Supinski GS, Netzel PF, Westgate PM, *et al.* A randomized controlled trial to determine whether beta-hydroxy-beta-methylbutyrate and/or eicosapentaenoic acid improves diaphragm and quadriceps strength in critically ill mechanically ventilated patients. *Crit Care* 2021; 25:308.
46. Wittholz K, Fetterplace K, Ali Abdelhamid Y, *et al.*  $\beta$ -Hydroxy- $\beta$ -methylbutyrate (HMB) supplementation and functional outcomes in multitrauma patients: a study protocol for a pilot randomised clinical trial (BOOST trial). *Pilot Feasibil Stud* 2022; 8:21.
47. Heyland DK, Wibbenmeyer L, Pollack JA, *et al.* A Randomized trial of enteral glutamine for treatment of burn injuries. *N Engl J Med* 2022; 387:1001–1010.
- This is the largest multicentre RCT of glutamine supplementation in burn injuries, which demonstrated no benefit from such supplementation, in contrast to previous single-centre RCTs. The findings suggest that results of single-centre trials should not be translated into clinical practice guidelines until rigorous multicentre trials are conducted.
48. Ham DJ, Caldwell MK, Chhen V, *et al.* Glycine restores the anabolic response to leucine in a mouse model of acute inflammation. *Am J Physiol Endocrinol Metab* 2016; 310:E970–E981.
49. Genton L, Teta D, Pruijm M, *et al.* Glycine increases fat-free mass in malnourished haemodialysis patients: a randomized double-blind crossover trial. *J Cachexia Sarcopenia Muscle* 2021; 12:1540–1552.